<DOC>
	<DOCNO>NCT02854033</DOCNO>
	<brief_summary>Since launch 2004 , overarch aim Alzheimer 's Disease Neuroimaging Initiative ( ADNI ) realize inform design therapeutic trial AD . ADNI3 continue previously fund ADNI-1 , ADNI-GO , ADNI-2 study combine public/private collaboration academia industry determine relationship clinical , cognitive , image , genetic biochemical biomarker characteristic entire spectrum Alzheimer 's disease ( AD ) . The overall goal study continue discover , optimize , standardize , validate clinical trial measure biomarkers use AD research .</brief_summary>
	<brief_title>Alzheimer 's Disease Neuroimaging Initiative 3 ( ADNI3 ) Protocol</brief_title>
	<detailed_description>The overall goal ADNI3 determine relationship among clinical , cognitive , image , genetic biochemical biomarker characteristic entire spectrum Alzheimer 's disease ( AD ) , pathology evolves normal age mild symptom , mild cognitive impairment ( MCI ) , dementia . ADNI3 continue previously fund AD Neuroimaging Initiative ( ADNI1 , ADNI-GO , ADNI-2 ) , remain public/private collaboration academia industry study biomarkers AD . ADNI continue inform neuroscience AD , identify diagnostic prognostic marker , identify outcome measure use clinical trial , help develop effective clinical trial scenario . This non-randomized natural history non-treatment study . Participants need 55 - 90 year , otherwise healthy neurologic disease Alzheimer 's disease . Approximately 1070 - 2000 participant enrol approximately 59 site United States Canada . Approximately , 700 - 800 rollover participant previous ADNI study , 370 - 1200 newly enrol . Clinical/cognitive , imaging , biomarker , genetic characteristic assess across three cohort . Subjects undergo longitudinal clinical cognitive assessment , computerize cognitive battery , biomarker genetic test , PET ( FDG , amyloid tau ) MRI scan cerebral spinal fluid ( CSF ) collection 5 year .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<criteria>Inclusion Criteria ( CN participant ) : 1 . Participant without subjective memory complaint , verify study partner , beyond one would expect age 2 . Normal memory function document score education adjust cutoff Logical Memory II subscale ( Delayed Paragraph Recall , Paragraph A ) Wechsler Memory Scale Revised ( maximum score 25 ) : 1 . 9 16 year education 2 . 5 815 year education 3 . 3 07 year education 3 . MiniMental State Exam score 24 30 inclusive ( Exceptions may make participant le 8 year education discretion Project Director ) 4 . Clinical Dementia Rating = 0 . Memory Box score must 0 5 . Cognitively normal , base absence significant impairment cognitive function activity daily live 6 . Stability Permitted Medications least 4 week : 1 . Stable dos antidepressant lack significant anticholinergic side effect ( currently adequately treat depressive symptom history major depression within past 1 year ) 2 . Estrogen replacement therapy permissible 3 . Gingko biloba permissible , discourage 4 . Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen . Inclusion Criteria ( MCI participant ) : 1 . Participant must express subjective memory concern report participant , recall study partner clinician . 2 . Abnormal memory function document score education adjust cutoff Logical Memory II subscale ( Delayed Paragraph Recall , Paragraph A ) Wechsler Memory Scale Revised ( maximum score 25 ) : . &lt; 11 16 year education b . ≤ 9 815 year education c. ≤ 6 07 year education 3 . MiniMental State Exam score 24 30 inclusive ( Exceptions may make participant le 8 year education discretion Project Director ) 4 . Clinical Dementia Rating = 0.5 . Memory Box score must least 0.5 5 . General cognition functional performance sufficiently preserve diagnosis Alzheimer 's disease make site physician time Screening Visit 6 . Stability Permitted Medications least 4 week : 1 . Stable dos antidepressant lack significant anticholinergic side effect ( currently adequately treat depressive symptom history major depression within past 1 year ) 2 . Cholinesterase inhibitor memantine allowable stable 12 week prior Screening Visit 3 . Estrogen replacement therapy permissible 4 . Gingko biloba permissible , discourage 5 . Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen . Inclusion Criteria ( AD participant ) : 1 . Participant must express subjective memory concern report participant , recall study partner clinician.n . 2 . Abnormal memory function document score education adjust cutoff Logical Memory II subscale ( Delayed Paragraph Recall , Paragraph A ) Wechsler Memory Scale Revised ( maximum score 25 ) : 1 . ≤ 8 16 year education 2 . ≤ 4 815 year education 3 . ≤ 2 07 year education 3 . MiniMental State Exam score 20 24 inclusive ( Exceptions score 24 25 may make participant le 8 year education discretion Project Director ) 4 . Clinical Dementia Rating = 0.5 1.0 5 . NINCDS ( National Institute Neurological Communicative Disorders Stroke ) ADRDA ( Alzheimer 's Disease Related Disorders Association ) criteria probable AD 6 . Stability Permitted Medications least 4 week : 1 . Stable dos antidepressant lack significant anticholinergic side effect ( currently adequately treat depressive symptom history major depression within past 1 year ) 2 . Cholinesterase inhibitor memantine allowable stable 12 week prior Screening Visit 3 . Estrogen replacement therapy permissible 4 . Gingko biloba permissible , discourage 5 . Washout psychoactive medication ( e.g. , excluded antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic , etc . ) least 4 week prior screen . Inclusion Criteria Specific Newly Enrolled Participants 1 . Geriatric Depression Scale score less 6 . 2 . Age 5590 year ( inclusive ) . 3 . Study partner frequent contact participant ( i.e. , minimum average 10 hour per week ) available accompany participant clinic visit duration protocol . 4 . Visual auditory acuity adequate neuropsychological testing . 5 . Good general health disease expect interfere study . 6 . Participant pregnant , lactating , childbearing potential ( i.e . woman must two year postmenopausal surgically sterile ) . 7 . Willing able participate longitudinal imaging study . 8 . Modified Hachinski Ischemic Score less equal 4 . 9 . Completed six grade education good work history ( sufficient exclude mental retardation ) . 10 . Must speak English Spanish fluently . 11 . Willing undergo repeat MRIs ( 3Tesla ) least two PET scan 12 . Agrees collection blood genomic analysis ( include GWAS ( genomewide association study ) sequence analysis ) , APOE ( Apolipoprotein E ) test biospecimen bank . 13 . Agrees collection blood biomarker test . 14 . Agrees least one lumbar puncture collection CSF . 15 . Agrees share genomic data biomarker sample . Inclusion Criteria Specific Rollover Participants '' The following additional inclusion criterion apply diagnostic category rollover participant : 1 . Must enrol follow ADNI1 , ADNIGO , ADNI2 least one year . 2 . Willing able continue participate ongoing longitudinal study . A reduced battery test allowable participant able/willing complete full battery . Exclusion Criteria ( CN participant ) : 1 . Any significant neurologic disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic deficit know structural brain abnormality Exclusion Criteria ( MCI participant ) : 1 . Any significant neurologic disease suspect incipient Alzheimer 's disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic deficit know structural brain abnormality . Exclusion Criteria ( AD participant ) : 1 . Any significant neurologic disease Alzheimer 's disease , Parkinson 's disease , multiinfarct dementia , Huntington 's disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , history significant head trauma follow persistent neurologic deficit know structural brain abnormality . Exclusion Criteria ( participant ) : The following additional exclusion criterion apply diagnostic category : 1 . Screening/Baseline MRI brain scan evidence infection , infarction , focal lesion multiple lacunes lacunes critical memory structure 2 . Subjects contraindication MRI study , include presence cardiac pacemaker , metal fragment foreign object eye , skin body . 3 . Major depression , bipolar disorder describe DSMIV within past 1 year . Psychotic feature , agitation behavioral problem within last 3 month could lead difficulty comply protocol . 4 . Currently treat medication obsessivecompulsive disorder attention deficit disorder . 5 . History schizophrenia ( DSM IV criterion ) . 6 . History alcohol substance abuse dependence within past 2 year ( DSM IV criterion ) . 7 . Any significant systemic illness unstable medical condition , could lead difficulty comply protocol . 8 . Clinically significant abnormality B12 thyroid function test ( TFTs ) might interfere study . A low B12 exclusionary , unless followup lab ( homocysteine ( HC ) methylmalonic acid ( MMA ) ) indicate physiologically significant . 9 . Residence skilled nursing facility . 10 . Current use specific psychoactive medication ( e.g. , certain antidepressant , neuroleptic , chronic anxiolytic sedative hypnotic ) . Current use warfarin anticoagulant dabigatran , rivaroxaban apixaban ( exclusionary lumbar puncture ) . 11 . Current use exclusionary medication 12 . Investigational agent prohibit one month prior entry duration trial . 13 . Participation clinical study involve neuropsychological measure collect one time per year . Exclusion Criteria Specific AV1451 PET : The follow criterion exclusionary AV1451 scan portion study : 1 . History risk factor torsades de pointes ( cardiac dysrhythmia associate sudden death ) take medication know prolong QT interval . A list restrict medication provide . 2 . Have ECG obtain prior AV1451 PET scan opinion investigator clinically significant regard subject 's participation study . Bazett 's correct QT ( QTcB ) interval must evaluate must exceed 458 msec male , 474 msec female .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>amyloid</keyword>
	<keyword>plaque</keyword>
	<keyword>neuroimaging</keyword>
	<keyword>biomarkers</keyword>
	<keyword>cognition disorder</keyword>
	<keyword>early detection</keyword>
	<keyword>pre-dementia</keyword>
	<keyword>dementia</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>tau</keyword>
</DOC>